Coronavirus News Roundup: Pfizer Files for EUA for COVID-19 Vaccine, OWS Ready to Deploy 40 Million Vaccine Doses by End of Year
Here's the roundup of this week's coronavirus-related news.
The number of coronavirus disease 2019 (COVID-19) cases in the United States continue to reach record highs, with approximately 80,698 COVID-19––related hospitalizations as of November 19, according to The COVID Tracking Project. This week, Pfizer announces that they have submitted their vaccine candidate for FDA authorization, and Operation Warp Speed (OWS) officials said they are ready to distribute COVID-19 vaccines to all jurisdictions within 24 hours after FDA authorization.
Here’s a roundup of the latest coronavirus-related news:
FDA Grants EUA to Baricitinib-Remdesivir Combination for COVID-19 Treatment
The FDA has granted an EUA to Eli Lilly and Company and Incyte for baricitinib in combination with remdesivir in hospitalized patients with suspected or confirmed COVID-19 infection.
Pfizer, BioNTech to Submit EUA Request to FDA Today for COVID-19 Vaccine
Pfizer and BioNTech will file for emergency use authorization (EUA) to the FDA on Friday for their COVID-19 vaccine candidate BNT162b2, according to a press release.
US Expects 40 Million COVID-19 Vaccine Doses to be Available in December
OWS officials announced that about 40 million doses of 2 safe and highly effective vaccines for COVID-19 – made by Moderna and Pfizer – could be available for distribution by the end of December, pending FDA approval.
Pfizer, BioNTech Plan to File EUA Request for COVID-19 Vaccine Within Days
Pfizer and BioNTech announced that their COVID-19 vaccine candidate showed 95% efficacy and no serious adverse effects (AEs), according to a final analysis of its phase 3 trial.
Moderna Reports 94.5% Efficacy for COVID-19 Vaccine Candidate
Moderna announced today that an interim analysis of its phase 3 trial for mRNA-1273, its vaccine candidate against COVID-19, showed 94.5% efficacy rate for the vaccine in preventing disease.
